Articles tagged with Liver Cancer
Researchers identified a previously unknown form of lymph node-like structures in liver tumors that are associated with greater treatment response and lower recurrence rates. The structures, found in patients treated with immune checkpoint inhibitors, contain infection-fighting immune B cells and tumor-killing immune T cells.
Researchers found that WNTinib significantly delayed tumour growth and extended survival in mice with hepatoblastoma cells harboring CTNNB1 mutations. The treatment also showed promise in shrinking tumors in patients' tumor tissue models, with some tumors disappearing completely.
Researchers at VCU Massey Comprehensive Cancer Center are exploring a new approach to treating liver cancer using immunotherapy and a newly developed drug that inhibits the MYC gene. The four-year grant aims to identify effective treatment combinations for hepatocellular carcinoma, improving patient survival rates.
Researchers investigate how liver necroptosis triggers inflammation in both organs, leading to cognitive impairment. Studying aging mouse models, they found that liver necroptosis causes systemic inflammation affecting brain function.
A new study has found that using a higher dosage of radioembolisation treatment with yttrium-90 microspheres can improve overall survival outcomes for liver cancer patients. Patients who received this elevated dose had significantly better results, with some experiencing prolonged survival and even curative treatments.
A new algorithm, Modified Metroticket, has been developed to predict overall survival and recurrence-free survival in patients with intermediate-stage liver cancer. The tool takes into account tumour burden, biological aggressiveness, liver function, and age, and has been validated using local and international datasets.
A recent study published in Liver Cancer found that patients with diabetes mellitus and comorbid obesity are at a higher risk of liver cancer recurrence after resection. The risk is significantly higher for those with comorbid obesity, increasing by approximately 3.8 times over five years postoperatively.
The #HOPE4LIVER trial demonstrated the safety and efficacy of histotripsy as a treatment for primary and metastatic liver tumors, achieving a 95% technical success rate. The procedure's non-invasive nature and ability to spare critical vessels and bile ducts offer promising alternatives to traditional treatments.
A recent study found a correlation between higher anti-PD-1 autoantibody levels and lower survival rates in patients with advanced liver cancer, suggesting these autoantibodies as potential biomarkers for predicting treatment response. The discovery aims to improve treatment regimens for patients with liver cancer.
A new study published in Cell Systems uses artificial intelligence to map regulatory networks in patient tumors and identifies four drug candidates for neuroendocrine, liver, and renal cancers. The researchers validated these candidates in cells, showing that inhibiting them significantly affected cancer cell growth.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers at Sanford Burnham Prebys discovered that specific macrophage subpopulations, including TREM2+, are critical for resolving MASH and liver fibrosis. These cells help reduce inflammation, slow disease progression, and promote healing.
A new study by Korea University College of Medicine shows that direct-acting antivirals significantly reduce liver-related clinical outcomes and lower the risk of disease progression to cancer or cirrhosis, increasing life expectancy for patients with Hepatitis C. The treatment approach has a high effectiveness rate of 90%.
The Chinese College of Interventionalists has introduced a consensus statement on TACE refractoriness in hepatocellular carcinoma, providing a framework for clinicians to identify and manage the condition. This move aims to optimize treatment strategies and improve patient outcomes, particularly in China where HCC incidence is high due...
The study analyzes six major digestive system cancers worldwide and in China, revealing correlations between country HDI and cancer prevalence. Colorectal cancer is the most prevalent, while Asia accounts for 60.5% of new gastrointestinal cancer cases globally.
Patients with high-risk liver cancer who received neoadjuvant immunotherapy before surgery had comparable outcomes to those who received surgery upfront. Successful resection rates were higher among those treated with immunotherapy, leading to improved median recurrence-free survival.
A study of non-statin cholesterol-lowering medications found that cholesterol absorption inhibitors were associated with a 31% lower odds of liver cancer risk. Statin use was also linked with a 35% lower risk. Fibrates, omega-3 fatty acids, and niacin showed no association.
Researchers explore various immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, as promising treatments for hepatocellular carcinoma. The review aims to overcome current limitations of targeted therapies by regulating the body's immune systems.
Researchers have identified microproteins exclusive to liver tumors that can stimulate the immune system against cancer cells. These small molecules, generated from previously non-coding genes, could be used to develop new treatments, including vaccines that stop or reduce tumor growth.
Researchers found that regorafenib synergizes with TAS102 to inhibit cancer growth, angiogenesis, and microvessel density in preclinical models of colorectal and gastric cancers. The combination also suppresses ERK1/2 activation regardless of KRAS or BRAF mutational status.
Researchers at Weill Cornell Medicine have identified cellular and molecular markers that can predict when pancreatic cancer will spread to the liver or other organs. The study found that patients with early-stage pancreatic cancer who showed signs of immune exhaustion were more likely to develop liver metastases.
A recent study published in Journal of Hepatology found that over 40% of liver cancer samples harbor more than one molecular subtype, leading to a
Researchers discuss primary hepatic angiosarcoma, a rare mesenchymal liver tumor, and its poor prognosis compared to hepatocellular carcinoma. Diagnosing PHA is critical due to its similar clinical presentation to HCC.
This review examines the intricate signaling pathways in colorectal cancer, highlighting key roles in tumorigenesis and potential therapeutic targets. Strategies to overcome resistance and novel approaches, such as colonic organoids, are also discussed.
Researchers have discovered that a rare liver cancer called fibrolamellar carcinoma is not caused by the fusion of two genes, but by the overexpression of a protein called protein kinase A. This finding has potential to reveal pathways for broad range of cancers and offer new treatment possibilities.
A new study has identified disparities in liver transplant referral and evaluation that occur before waitlisting for patients with early-stage liver cancer. These disparities affect older, poorer, Black, and Medicaid beneficiaries, highlighting the need for targeted interventions to improve equity in access to liver transplantation.
Researchers found high GDF15 levels in steatotic liver patients are associated with an increased risk of liver cancer. Combining blood GDF15 levels with liver stiffness indicators can efficiently identify patients at high risk of developing liver cancer and poor outcomes.
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
New cancer projections highlight progress in reducing incidence rates for common cancers like lung, colorectal, and prostate, but also warn of rising rates for less common types such as liver, kidney, melanoma, and non-Hodgkin lymphoma.
A 5:2 diet has been shown to protect against chronic liver inflammation and liver cancer in mice. The study identified two proteins, PPARα and PCK1, that are jointly responsible for the protective effect of fasting.
Liver cancer mortality in China decreased from 2008 to 2020, with higher rates among males, older adults, and rural populations. The study predicts a downward trend for liver cancer mortality in the next decade.
A new study suggests that proteins detectable in the blood could improve predictions about risk of liver cancer, potentially leading to earlier therapeutic interventions. The researchers used proteomics to develop a prediction model and identified 56 plasma proteins associated with liver cancer.
A study from Medical University of Vienna reveals a new molecular signaling pathway crucial to liver cancer development, offering potential new therapeutic targets. The research also identifies the c-Jun/Fra-2 complex as essential in triggering tumour growth.
A review of A-HCC highlights the connection between heavy drinking and the risk of this aggressive form of liver cancer. The study proposes developing better diagnostic tools and treatment options through understanding how alcohol contributes to its development.
Researchers have developed a new treatment that uses tailored doses of anti-cancer drugs released directly into the surgical cavity to treat liver cancer. The approach has shown promise in reducing recurrence rates and minimizing chemotherapy side effects, with potential applications for other types of cancer.
A population-wide observational study found an association between tuberculosis (TB) and a higher incidence of various cancers. TB patients were more likely to be diagnosed with lung, blood, gynaecological, colorectal, thyroid, oesophagus, and stomach cancers compared to the general population.
A faulty beta-catenin gene helps tumours evade immunity by stopping tumor cells releasing message-containing cargoes called exosomes. Silencing mutant-beta-catenin could be a viable therapeutic strategy to trigger immune cell infiltration and increase tumour-to-immune cell communication.
A study found that maternal obesity increases the risk of developing liver disease and liver cancer in offspring, due to the transmission of an altered gut microbiota. The risk is significantly higher in mice fed a junk food diet, highlighting the importance of microbiome health.
Research reveals oestrogen's protective role in preventing fatty liver disease by targeting the TEAD1 protein. The discovery could lead to a new treatment for fatty liver and liver cancer, as well as earlier detection methods.
A University of Cincinnati study found real-time navigation enhances precision in liver cancer ablation, with improved accuracy for less experienced surgeons. The technology provides detailed information on tumor location, reducing damage to surrounding healthy tissue.
A study by UC Davis Health found that a single dose of BCG reduced liver tumor burden and extended the survival of mice with liver cancer. The vaccine boosted the body's immunity, leading to tumor shrinkage and improved liver function.
Recent US nationwide data reveal rising HCC incidence and mortality rates primarily affecting men and older adults. The study highlights disparities among racial/ethnic groups and underscores the need for targeted early detection, intervention, and treatment strategies to improve patient outcomes.
Researchers have developed magnet-guided microrobots that can target and treat liver tumors using an MRI device. The robots are guided by a magnetic field and use gravity to navigate to the tumor, preserving healthy cells.
Researchers identified blood proteomic markers associated with hepatocellular carcinoma (HCC) in patients with cirrhosis. The study found a set of biomarkers, including TGF-β driven mechanistic biomarkers and Myostatin and Pyruvate Kinase M2, which may stratify risk for HCC.
Korea University researchers found that perioperative radiotherapy significantly improves survival rates among HCC patients at high risk of recurrence. The study suggests that radiotherapy can reduce recurrence and improve survival in these patients, providing a significant adjuvant treatment option.
Researchers found that people with Type 2 diabetes have higher levels of AGEs, leading to more viscoelastic liver tissue, which increases the risk of liver cancer. The study suggests new screening guidelines for this population, potentially improving early detection and treatment.
A recent study discovered a causal link between oncofoetal ecosystems and liver cancer recurrence, highlighting their potential as biomarkers for treating hepatocellular carcinoma (HCC). The research found that oncofoetal reprogramming contributes to EMT, tumour cell proliferation, and response to immunotherapy.
UCLA surgeons and scientists present research on ethnic predictors of gastric cancer survival, early liver retransplantation and risk factors for chemical restraint use in adult trauma patients. The studies highlight the importance of understanding these factors to improve patient care.
A recent study by University of Missouri researcher Mansoo Yu found that online weight loss interventions with counseling and social support are effective for middle-aged adults with obesity. The study identified two key features: professional health coaching and access to social support from other users, which led to significant long-...
A nationwide study from Karolinska Institutet found that GLP1 agonists like Ozempic reduce the risk of cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease. Those who continued taking the medication for ten years were half as likely to develop severe liver disease.
A new study reveals that RNA binding motif protein X-linked (RBMX) plays a crucial role in predicting cancer prognosis and response to immunotherapy. Abnormal expression of RBMX is associated with immune regulation, tumor microenvironment, and therapeutic effects of immune checkpoint inhibitors.
The £30M ADVANCE study aims to accelerate the development of new therapies for people with liver cirrhosis by identifying translational biomarkers. Researchers will enroll 200 patients with cirrhosis and use advanced techniques to analyze gene expression, blood tests, and MRI scans.
A new study from the University of Pennsylvania School of Medicine found that mailing signed orders to patients with cirrhosis led to a significant increase in liver cancer screenings. The study involved over 500 patients and showed that 55% completed their screening within six months, compared to just 27% in the control group.
Researchers at HKUMed successfully cured stage 4 liver cancer by reducing it to stage 1 using a combination of stereotactic body radiation and immunotherapy, followed by successful removal through living donor liver transplantation. An 85-year-old patient with two liver cancers was also treated and recovered well.
Researchers discovered that Nectandrin B, a bioactive lignan compound from nutmeg, extends the lifespan of Drosophila melanogaster by as much as 42.6%. The study found that Nectandrin B reduces intracellular ROS levels and improves age-related symptoms such as locomotive deterioration and neurodegeneration.
A recent study from Drexel University's College of Nursing and Health Professions aimed to understand the challenges and supports affecting individuals with GI cancer and their caregivers when it comes to maintaining a healthy diet and avoiding malnutrition. The research highlighted the importance of creating dietary interventions that...
Researchers at UC Davis Comprehensive Cancer Center have shown that inhibiting galectin 1 protein using gene therapy can shrink liver cancer in mice, improving the anti-cancer immune response and increasing killer T cells. This approach has potential as a treatment for HCC prevention.
US-born Latinos have a higher incidence of liver cancer than foreign-born Latinos, suggesting lifestyle and cultural differences may contribute to the trend. Researchers found second and third generation Mexican Americans had a 37% and 66% higher risk of liver cancer, respectively.
A study by the Keck School of Medicine of USC found that liver cancer risk increases with each successive generation of Mexican Americans, particularly among men. The research analyzed data from over 30,000 participants and found third-generation Mexicans to be 66% more likely to develop liver cancer than first-generation individuals.
Scientists at Nagoya University have discovered a reliable cancer marker, stromal cell-derived factor 4 (SDF-4), that detects gastric cancer with high accuracy. The protein is found in high levels even in patients with stage I gastric cancer, suggesting its potential for early detection.